Erschienen in:
26.09.2022 | ASO Author Reflections
ASO Author Reflections: Commercialization of Adaptive Cell Therapy for Metastatic Melanoma
verfasst von:
Keshav Kooragayala, MD, Johanna Lou, MD, Young Ki Hong, MD, MPH
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 1/2023
Einloggen, um Zugang zu erhalten
Excerpt
The identification of the antitumor effects of programmed death ligand-1 (PD-1) cytotoxic T-cell lymphocyte 4 (CTLA-4) in the 2000s quickly led to their utilization in treating metastatic melanoma (MM) with some success. Ipilimumab (anti-CTLA-4) was the first immunotherapy approved for the treatment of MM, with the subsequent approval of PD-1 monotherapy in the KEYNOTE-006 trial.
1 In 2015, additional data demonstrated a robust, durable response for patients receiving ipilimumab + nivolumab therapy in the Checkmate-067 trial,
2 which is currently the standard of care regimen for MM. While these therapies have significant promise and highlight the ongoing advancement in managing patients with MM, they are limited by treatment-related toxicities
3 and modest response, prompting a need for additional treatment for patients who progress on these regimens. …